TABLE 2.
Cross-reactivity of antibodies from four groups of human patient serum specimens against ZIKV and DENV-2/3 wt VLP and NS1 antigens
| Serum panel (no. of samples) | No. cross-reactive/total no. tested (%)a
|
|||
|---|---|---|---|---|
| ZIKV-wt-VLP-MAC-ELISA | ZIKV-NS1-MAC-ELISA | DENV2/3-wt-VLP-MAC-ELISAb | DENV2-NS1-MAC-ELISA | |
| ZIKV (21) | 21/21 (100) | 21/21 (100) | 20/21 (95.2)* | 12/21 (57.1)* |
| Acute (23) | 16/23 (69.6) | 16/23 (69.6) | 22/23 (95.7)** | 2/23 (8.7)** |
| Convalescent (19) | 18/19 (94.7) | 19/19 (100) | 19/19 (100)*** | 10/19 (52.6)*** |
| WNV (56) | 2/56 (3.6) | 0/56 (0) | NA | NA |
| DENV (44) | 28/44 (63.6) | 32/44 (72.7) | 42/44 (95.5) | 40/44 (90.9) |
| Acute (40) | 17/40 (42.5) | 25/40 (62.5) | 26/40 (65.0) | 23/40 (57.5) |
| Convalescent (42) | 23/42 (54.8) | 24/42 (57.1) | 40/42 (95.2) | 38/42 (90.5) |
| Other (76) | 0/76 (0) | 0/76 (0) | 0/76 (0) | 2/76 (2.6) |
a
NA, not available. *, P = 0.0042, with significance level at 0.05; **, P < 0.0001, with significance level at 0.05; ***, P = 0.0007, with significance level at 0.05.
b
The cutoff for DENV-2/3 VLP or NS1-MAC-ELISA was based on our previous publication (24).